In-Flight COVID Transmission: Surveying the Liability Landscape
Do airlines have legal obligations to manage the risk of in-flight infections?
In-Flight COVID Transmission: Surveying the Liability Landscape

Author
Do airlines have legal obligations to manage the risk of in-flight infections?

By Christopher Robertson Speaking yesterday at America’s Health Insurance Plans’ (AHIP) National Health Policy Conference, FDA Commissioner Scott Gottlieb railed against patient cost-exposure (e.g., copays). His prepared speech said: Patients shouldn’t be penalized by their biology…
By Christopher Robertson and Kelly McBride Folkers In 2014, Arizonans overwhelmingly voted in favor of a ballot referendum that claimed to allow terminally ill patients the “right to try” experimental drugs that have not yet…
By Christopher Robertson This blog has often covered the problem of outrageous medical bills, and explored whether patients have a responsibility to pay the balance on charges that are not covered by insurance. One common…
By Christopher R. Robertson Over at HuffPo, Craig Konnoth has a short-but-smart piece exploring the Constitutionality of the logrolling deals now underway to persuade Alaska Senator Lisa Murkoswki to support the latest effort to repeal…
By Christopher Robertson The Federal government has wrested billions of dollars from the drug and device industry in settlements of claims that the companies broke the law by promoting their products “off-label” for uses not approved by…
By Christopher Robertson In a recent story about how the health insurance marketplaces are being destabilized by the Trump administration’s vacillation, the LA Times reports: At one recent meeting, Seema Verma, whom Trump picked to…
By Christopher Robertson Scholars and policymakers have long been concerned that the biomedical science literature — and thus the practice of medicine — is biased by the companies who fund research on their own products. Prior research…
By Christopher Robertson To limit liability and increase predictability, scholars and policymakers have long focused on capping damages awards. In particular, they have been worried that there are many runaway jury awards for non-economic damages…
By Christopher Robertson As many readers of this blog know, the FDA requires that, prior to entering the market, companies prove safety and efficacy for each intended use of their products, but physicians are then free to…